Difference between revisions of "Vandetanib (Caprelsa)"
m |
m |
||
| Line 27: | Line 27: | ||
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
*2012-02-16: Initial marketing authorization as Caprelsa. | *2012-02-16: Initial marketing authorization as Caprelsa. | ||
| + | ==History of changes in Health Canada indication== | ||
| + | *2012-01-12: Initial notice of compliance | ||
==History of changes in PMDA indication== | ==History of changes in PMDA indication== | ||
*2015-09-28: Initial approval for the treatment of unresectable [[Thyroid cancer, medullary|medullary thyroid cancer]]. | *2015-09-28: Initial approval for the treatment of unresectable [[Thyroid cancer, medullary|medullary thyroid cancer]]. | ||
| Line 53: | Line 55: | ||
[[Category:EMA approved in 2012]] | [[Category:EMA approved in 2012]] | ||
[[Category:FDA approved in 2011]] | [[Category:FDA approved in 2011]] | ||
| + | [[Category:Health Canada approved in 2012]] | ||
[[Category:PMDA approved in 2015]] | [[Category:PMDA approved in 2015]] | ||
Revision as of 11:51, 15 June 2023
General information
Class/mechanism: from the NCI Drug Dictionary: "An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis." Also a tyrosine kinase inhibitor of RET (rearranged during transfection), BRK (breast tumor kinase/protein tyrosine kinase 6), TIE2, EPH, Src. Inhibits angiogenesis, endothelial cell migration, and tumor growth.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Toxicity management
Diseases for which it is established (work in progress)
Diseases for which it is used
Patient drug information
- Vandetanib (Caprelsa) package insert[5]
- Vandetanib (Caprelsa) patient drug information (Chemocare)[6]
- Vandetanib (Caprelsa) patient drug information (UpToDate)[7]
History of changes in FDA indication
- 2011-04-06: Initial approval for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. (Based on ZETA)
History of changes in EMA indication
- 2012-02-16: Initial marketing authorization as Caprelsa.
History of changes in Health Canada indication
- 2012-01-12: Initial notice of compliance
History of changes in PMDA indication
- 2015-09-28: Initial approval for the treatment of unresectable medullary thyroid cancer.
Also known as
- Code names: AZD6474, ZD6474
- Brand names: Caprelsa, Lucivand, Zactima
References
- ↑ 1.0 1.1 Vandetanib (Caprelsa) package insert
- ↑ Vandetanib (Caprelsa) package insert (locally hosted backup)
- ↑ Caprelsa manufacturer's website
- ↑ Caprelsa Risk Evaluation and Mitigation Strategy (REMS) Program
- ↑ Vandetanib (Caprelsa) package insert
- ↑ Vandetanib (Caprelsa) patient drug information (Chemocare)
- ↑ Vandetanib (Caprelsa) patient drug information (UpToDate)
- Drugs
- Oral medications
- EGFR inhibitors
- PDGFR inhibitors
- RET inhibitors
- SRC inhibitors
- TEK inhibitors
- VEGFR inhibitors
- Non-small cell lung cancer medications
- Thyroid cancer, differentiated medications
- Thyroid cancer, medullary medications
- REMS program
- EMA approved in 2012
- FDA approved in 2011
- Health Canada approved in 2012
- PMDA approved in 2015